calcimimetic peptide
Etelcalcetide
Answer
Etelcalcetide is authorised or registered in the US, the EU, the UK, Switzerland, Serbia, Singapore and Turkey: 7 of the 10 registers read. Highest trial phase: Phase 3 (1 phase 3 trial, 0 with posted results). It has 24 registered trials, 3 of them running. Brand names on the FDA label register: Parsabiv.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
24 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 16 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 1 trial carries no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Not on the register | Health Canada, ca-dpd | 2026-09-03 |
| Australia | Status unknown | TGA, au-artg | not read |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Not on the register | ANVISA, br-anvisa | 2026-09-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Etelcalcetide changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 24 trials
| NCT03969329 | A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis currently recruiting participants · register updated 2026-08-21 |
|---|---|
| NCT06690242 | MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease completed · register updated 2026-07-22 |
| 2023-506471-10-00 | Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Chil no status recorded · register updated 2026-06-10 |
| NCT03633708 | A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis currently recruiting participants · register updated 2026-02-27 |
| NCT06352957 | Use of ETElcalcetidefor pReserving vitamiN K-dependent proteIn activiTY ITAlian Study not yet recruiting participants · register updated 2024-04-08 |
| NCT03960437 | The Effect of Etelcalcetide on CKD-MBD completed · register updated 2023-09-21 |
| NCT03795558 | A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dial completed · register updated 2022-03-23 |
| NCT03299244 | Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) completed · register updated 2021-04-30 |
| NCT03182699 | Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients completed · register updated 2020-06-09 |
| NCT03527511 | Effect of Active Vitamin D and Etelcalcetide on Human Osteoclasts in Patients With Chronic Kidney Disease completed · register updated 2020-03-31 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.